Mengzhen Lai

State Key Laboratory Of Drug Research
Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor.

Sphingosine-1-Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third-Generation EGFR Inhibitor.

Journal: MedComm

Published: July 25, 2025

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.

Journal: Signal transduction and targeted therapy

Published: November 20, 2023

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Journal: Molecular cancer

Published: August 19, 2023

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.

A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.

Journal: Cancer communications (London, England)

Published: August 01, 2023

Design, synthesis and biological evaluation of KRASG12C-PROTACs.

Design, synthesis and biological evaluation of KRASG12C-PROTACs.

Journal: Bioorganic & medicinal chemistry

Published: December 09, 2022

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK.

ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK.

Journal: Frontiers in pharmacology

Published: October 15, 2022

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo.

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo.

Journal: Journal of Cancer

Published: August 05, 2022

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.

Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations.

Journal: Journal of medicinal chemistry

Published: April 21, 2022

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Journal: ACS medicinal chemistry letters

Published: October 10, 2021

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Journal: Molecular cancer

Published: August 18, 2021

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.

Journal: Cancer science

Published: May 09, 2021

Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors.

Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRASG12C inhibitors.

Journal: European journal of medicinal chemistry

Published: October 19, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026